COVID-19: Vaccines and Therapeutics
Cities, counties and other local governments may apply through April 20 for grants to work with community-based organizations to encourage COVID-19 safety and vaccination in vulnerable and underserved populations.
The Centers for Disease Control and Prevention released interim guidelines for fully vaccinated individuals’ social practices. CDC said that those who are fully vaccinated — whether the two doses required by the Pfizer and Moderna vaccines, or the single Johnson & Johnson dose — may eschew…
The Senate today voted 50-49 to approve a modified version of the American Rescue Plan Act of 2021, a $1.9 trillion COVID-19 relief package, which includes a number of provisions that affect hospitals and health systems. It is our understanding there may be some additional text changes to the bill…
A research letter published in the New England Journal of Medicine looks at delayed injection-site skin reactions to the Moderna COVID-19 vaccine four to 11 days after 12 people received the first dose.
The National Institutes of Health has halted a clinical trial evaluating the effectiveness of COVID-19 convalescent plasma in emergency department patients with mild-to-moderate COVID-19 symptoms and at least one risk factor for severe COVID-19 after an independent board concluded from the data…
President Biden today announced a major partnership between Johnson & Johnson and Merck to manufacture the latest COVID-19 vaccine to be authorized for emergency use in the U.S.
The federal government has agreed to purchase at least 100,000 doses of the combination monoclonal antibody therapy bamlanivimab and etesevimab, Eli Lilly and Company announced.
The Food and Drug Administration granted an emergency use authorization for Johnson & Johnson’s single-dose COVID-19 vaccine.
A summary of important information for providers on Johnson & Johnson’s COVID-19 vaccine.
The House of Representatives early this morning voted 219-212 to approve a modified version of the American Rescue Plan Act of 2021, legislation to provide reconciliation protection for a roughly $1.9 trillion COVID-19 relief package, which includes a number of provisions that affect hospitals and…
- Novel Coronavirus (SARS-CoV-2/COVID-19)
- Legislation and Legislative Advocacy
- Advocacy & Public Policy
- COVID-19: Vaccines and Therapeutics
- Medicaid
- Marketplace Issues/Stability
- Medicare DSH
- Substance Use Disorder
- Behavioral Health Intervention & Issues Prevention
- Workforce
- Skilled Nursing Facility PPS
- OSHA
- Rural issues